Detalhe da pesquisa
1.
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
N Engl J Med
; 384(3): 216-228, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186492
2.
Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.
Kidney Int
; 103(2): 403-410, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36341885
3.
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial.
Cardiovasc Diabetol
; 22(1): 52, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36899386
4.
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Lancet
; 398(10306): 1133-1146, 2021 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34469765
5.
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.
Eur Heart J
; 42(31): 2995-3007, 2021 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963372
6.
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
Eur Heart J
; 42(26): 2565-2573, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33197271
7.
Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries.
Circulation
; 141(24): 2004-2025, 2020 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32539609
8.
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial.
Stroke
; 52(8): 2494-2501, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33985364
9.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet
; 394(10193): 121-130, 2019 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189511
10.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet
; 394(10193): 131-138, 2019 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189509
11.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N Engl J Med
; 377(12): 1119-1131, 2017 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28845751
12.
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <â¯7% are associated with lower major cardiovascular events.
Am Heart J
; 225: 97-107, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32480059
13.
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Cardiovasc Diabetol
; 19(1): 199, 2020 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33239067
14.
Polypill in Persons without Cardiovascular Disease. Reply.
N Engl J Med
; 384(17): 1676-1677, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33913653
15.
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
N Engl J Med
; 374(21): 2009-20, 2016 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27041480
16.
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
N Engl J Med
; 374(21): 2032-43, 2016 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27039945
17.
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
N Engl J Med
; 374(21): 2021-31, 2016 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27040132
18.
Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial.
Am Heart J
; 216: 9-19, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31377568
19.
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
Am Heart J
; 206: 72-79, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30342297
20.
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
Diabetes Obes Metab
; 20(1): 42-49, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28573765